4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab
AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities
Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure.
Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody.
“We look forward to partnering with 4TEEN4 and working together to develop and manufacture this revolutionary treatment, and help it reach the critical clinical trial phase,” said Patricio Massera, Chief Executive Officer at AGC Biologics. “Our Chiba and Copenhagen sites have the proven experience and expertise to help 4TEEN4 in its journey towards the clinical and market supply of this new innovative therapy.”
4TEEN4 is a preclinical-stage biotech company dedicated to helping critically ill patients suffering from loss of heart function and circulatory shock. Its flagship biologic, Procizumab, is a humanized monoclonal antibody able to inhibit the activity of its target, Dipeptidyl Peptidase 3 (DPP3), stabilize cardiovascular function and potentially increase survival chances e.g., in cardiogenic and septic shock.
“AGC is a high-quality partner with global manufacturing expertise and extensive commercial supply experience, and we are pleased to start a long-standing relationship as we continue to progress in our clinical development,” said Andreas Bergmann, founder and CEO of 4TEEN4. “Preclinical studies of Procizumab in models of cardiovascular failure showed instant efficacy, demonstrating this treatment’s tremendous potential.”
The teams of scientists at AGC Biologics’ Chiba and Copenhagen facilities have more than 20 years’ experience developing and delivering a wide range of mammalian and microbial programs, including several commercially approved products. AGC Biologics also recently announced expansion plans for its facility in Copenhagen that will double the production capacity at the site and meet increasing market demand.
About 4TEEN4
4TEEN4 is dedicated to improving critically ill patient lives who suffer from hemodynamic instability, end-organ hypoperfusion and multiple organ failure with our first-in-class humanized monoclonal antibody “Procizumab” targeting human dipeptidyl peptidase 3 (DPP3). 4TEEN4 licensed its novel biomarker DPP3 for diagnostic purposes in critical care conditions. 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) was established in 2013 in Hennigsdorf near Berlin, Germany, by Dr. Andreas Bergmann, CEO of 4TEEN4, as part of his Medicine4Future Initiative. For further information, please visit www.4teen4.de
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
AGC Biologics Contact:
Media Contact: Nick McDonald
nmcdonald@agc.com
4TEEN4 Pharmaceuticals GmbH Contacts:
Investor Contact:
Dr. Karine Bourgeois
Tel: +49(0)1622145536
bourgeois@4teen4.de
Press Contact:
Leen Alsaka Amini
Tel: +49(0)1766 4322 193
amini@4teen4.de
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
NGS Group AB: NGS Groups företrädesemission övertecknad enligt preliminärt utfall26.4.2024 18:20:00 CEST | Pressemelding
Teckningsperioden i NGS Group AB:s (publ) (”NGS Group” eller ”Bolaget”) nyemission av aktier med företrädesrätt för befintliga aktieägare om ca 35,2 MSEK, före emissionskostnader (”Företrädesemissionen”) som beslutades av styrelsen den 29 februari 2024 och godkändes av den extra bolagsstämman den 26 mars 2024, avslutades idag den 26 april 2024. Det preliminära utfallet indikerar att teckningar och anmälningar om teckning med och utan stöd av teckningsrätter har erhållits motsvarande totalt cirka 145,6 procent av Företrädesemissionen. Slutligt utfall i Företrädesemissionen väntas offentliggöras genom pressmeddelande den 29 april 2024. Preliminärt utfall i Företrädesemissionen Teckningsperioden i Företrädesemissionen löpte fram till och med den 26 april 2024 och den preliminära sammanställningen visar att cirka 10 188 504 aktier, motsvarande cirka 94,1 procent av Företrädesemissionen tecknats med stöd av teckningsrätter. Därtill har teckningsanmälningar om cirka 5 570 754 aktier, motsvar
Millicom (Tigo) notice of first quarter 2024 results and video conference26.4.2024 18:13:53 CEST | Press release
Millicom (Tigo) notice of first quarter 2024 results and video conference Luxembourg, April 26, 2024 – Millicom expects to announce its first quarter 2024 results on May 8, 2024, via a press release. Millicom is planning to host a video conference for the global financial community on May 8, 2024, at 14:00 (Stockholm) / 13:00 (London) / 08:00 (Miami). Registration for the interactive event is required at the following link. After registering, you will receive a confirmation email containing details about joining the video conference. Participants who wish to ask a question during the live event must notify the Investor Relations team via email to investors@millicom.com after the start of the event. Participants may also join the conference in listen-only mode by dialing any of the following numbers and entering the Webinar ID: 822 3803 6738: US: +1 929 205 6099 Sweden: +46 850 539 728 UK: +44 330 088 5830 Luxembourg: +352 342 080 9265 Additional international numbers are available at t
Fly Play hf.: Ólafur Þór has decided to resign26.4.2024 18:03:00 CEST | Press release
Ólafur Þór Jóhannesson has decided to resign as Chief of Finance at PLAY airlines. Ólafur will remain as CFO at the company until his successor arrives. „Ólafur has been a great team member at PLAY. He was instrumental during the capital raise in Q1 and now leaves the company in a strong position. I wish Ólafur all the best in his upcoming ventures,“ says Einar Örn Ólafsson, CEO of PLAY. „I am truly grateful to have gotten the chance to be a part of this PLAY journey. After a successful capital raise, I feel it is the right time for me to step aside and turn my attention to other ventures. I would like to use this opportunity to wish PLAY and my colleagues all the best and I look forward to see the company take the next steps into a bright future,“ says Ólafur Þór Jóhannesson.
Implementation of new long-term share-based incentive programme26.4.2024 17:59:37 CEST | Press release
The board of directors of Svitzer Group A/S (the “Board of Directors”), CVR-no. 44791447, (“Svitzer Group” or the “Company”) has today decided to implement a new long-term share based incentive programme consisting of restricted share units (“RSUs”) for 2024 (the "LTI") and to implement an extraordinary share-based incentive programme in the form of one-off grants of RSUs related to completion of the demerger and separate listing of the Company ( “Extraordinary RSUs”) and grant a cash completion bonus to the members of the executive management and other eligible employees as also described in the prospectus published by Svitzer A/S on 22 March 2024. Long-term share-based incentive programme for 2024 The LTI for 2024 is share-based and designed to incentivise long-term performance, commitment, and retention of the members of the executive management and other eligible employees, as well as to promote alignment of their interests with those of the shareholders. Under the LTI for 2024, th
Svitzer Group A/S has now been established with contemplated first day of trading and official listing on Nasdaq Copenhagen A/S on 30 April 202426.4.2024 17:51:30 CEST | Press release
At the extraordinary general meeting of A.P. Møller - Mærsk A/S (“APMM”) held on 26 April 2024, it was resolved to complete the tax-exempt, partial demerger of APMM effected through a contribution of APMM’s shares in Svitzer A/S and its subsidiaries as well as certain other related assets and liabilities to a newly incorporated Danish limited liability company, Svitzer Group A/S (“Svitzer Group”). Thus, Svitzer Group has today been incorporated and registered with the Danish Business Authority with company registration number (CVR number) 44791447. The articles of association of Svitzer Group will be available on Svitzer Group’s website, www.svitzer.com. Svitzer Group has today submitted its application for admission to trading and official listing of its shares on Nasdaq Copenhagen A/S. The first day of trading and official listing of the shares in Svitzer Group on Nasdaq Copenhagen A/S is expected to take place on 30 April 2024 at 9.00 a.m. (CEST), under the permanent ISIN code DK006